International Companies

Merck & Co to spin off cancer unit ahead of Keytruda patent cliff

By Benjamin Chiou

Date: Monday 23 Feb 2026

(Sharecast News) - US pharma group Merck & Co is set to spin off its oncology operations in an effort to keep its wider healthcare businesses immune from a forthcoming patent cliff for its blockbuster Keytruda drug.
The firm is to split its healthcare business into two units: one housing its...

Sign up for free or to read the full story

Email this article to a friend

or share it with one of these popular networks:


Article Archive

Top of Page